According to a Form 8-K released on May 3rd, 2018, OWC Pharmaceutical Corp (OWCP) has received a $5 million investment from an Institutional Investor.

On April 30, 2018, OWC Pharmaceutical Research Corp. (the “Registrant”) entered into and consummated a Securities Purchase Agreement (the “Agreement”) with a non-US-based institutional investor (the “Purchaser”).   Under the terms and conditions of the Agreement, the Registrant sold and the Purchaser bought, (i) 500 shares of the Registrant’s new series of preferred stock designated as Series A Preferred Stock (the “Preferred Shares”), which are currently convertible into 37,500,000 shares of the Registrant’s common stock, par value $0.00001 per share (“Common Stock”) and (ii) Warrants (the “Warrants”) representing the right to acquire 12,500,000 shares of Common Stock (each of which shall be adjusted in accordance with the terms and conditions set forth in the Certificate of Designations and the Warrants) for an aggregate purchase price of $5,000,000. Newbridge Securities Corporation, through LifeTech Capital, acted as exclusive placement agent for the transaction. The Registrant paid Newbridge a cash fee and issued to them warrants to purchase 2.5 million shares of Common Stock.

I did some quick research on Newbridge Securities and found via their website and Google that they have several locations across the country – including a nicer area of Scottsdale, AZ that I’m familiar with. Their domain name ( was purchased in 2000, so they’ve definitely been in business since then. LifeTech Capital has definitely been in business since 2009, as their domain name ( was purchased in 2009. Under the “Investors” section of their website, it says:

Accredited investors receive the full benefit of access to our institutional research team and unique investment opportunities not available to the general public through our investment banking team. Many of our accredited investors are highly experienced in smallcap biotech investing including medical doctors and research Ph.D.s who can join our Investor-Advisor Panels and Seminars.

That, to me, is more reassurance that OWCP “checks out” and was seen as a genuine legit opportunity to this institutional investor, as LifeTech has their own research team AND these investors are highly experienced in biotech specifically.

The other good part of this finance method for current shareholders was:

The terms of each the Preferred Stock and Warrants provide for anti-dilution protection for issuances of shares of Common Stock at a price per share less than a price equal to the conversion price or exercise price, as applicable and, that in the event of a “fundamental transaction” (as described in the Warrants), the investor will have the right to receive the value of the Warrant as determined in accordance with the Black Scholes option pricing model.

It’s only May 3rd, so I’m still expecting more updates soon in regards to the Phase 1 Safety Studies that are going on and expected to complete in Quarter 2, according to the most recent “Investor Presentation” from OWCP’s website. I may update/add to this blog post later, as time allows.